Neuroendocrine Tumor Clinical Trials

134 recruitingLast updated: June 18, 2026

There are 134 actively recruiting neuroendocrine tumor clinical trials across 35 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Bethesda, Maryland, United States, Philadelphia, Pennsylvania, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Neuroendocrine Tumor Trials at a Glance

134 actively recruiting trials for neuroendocrine tumor are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 49 trials, with the heaviest enrollment activity in Bethesda, Philadelphia, and Nashville. Lead sponsors running neuroendocrine tumor studies include National Cancer Institute (NCI), IRCCS San Raffaele, and Hospices Civils de Lyon.

Browse neuroendocrine tumor trials by phase

Treatments under study

About Neuroendocrine Tumor Clinical Trials

Looking for clinical trials for Neuroendocrine Tumor? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 134 trials

Recruiting
Phase 2

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Unresectable Digestive System Neuroendocrine Tumor G1Unresectable Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)100 enrolled39 locationsNCT05773274
Recruiting
Phase 1

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 1

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Solid TumorNeuroendocrine TumorsGep Net+6 more
RayzeBio, Inc.104 enrolled9 locationsNCT07165132
Recruiting
Not Applicable

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Malignant Brain NeoplasmMalignant Solid NeoplasmProstate Carcinoma+2 more
Mayo Clinic147 enrolled1 locationNCT06788886
Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT02146170
Recruiting
Phase 2

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI)45 enrolled1 locationNCT06228066
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Breast CancerOvarian CancerProstate Cancer+6 more
University of Florida29 enrolled1 locationNCT05000294
Recruiting
Phase 2

CapTemY90 for Grade 2/3 NET Liver Metastases

Neuroendocrine TumorsNeuroendocrine Tumor Grade 2
Abramson Cancer Center at Penn Medicine70 enrolled4 locationsNCT04339036
Recruiting
Phase 2

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Not Applicable

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Prostate CancerThyroid CancerNeuroendocrine Tumors
Institut du Cancer de Montpellier - Val d'Aurelle350 enrolled4 locationsNCT04104529
Recruiting
Not Applicable

Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms

Rectal Neuroendocrine TumorsESDEPMR
Jilin University483 enrolled2 locationsNCT07612748
Recruiting

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Neuroendocrine Tumors
Ipsen150 enrolled34 locationsNCT07314164
Recruiting
Phase 2

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Breast CancerOvarian CancerNon-small Cell Lung Cancer+4 more
National Cancer Institute (NCI)285 enrolled1 locationNCT03412877
Recruiting
Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation

Neuroendocrine TumorsMEN1 Mutation
Centre Hospitalier Universitaire Dijon297 enrolled1 locationNCT06430021
Recruiting
Phase 2

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Metastatic Renal Cell CarcinomaNeuroendocrine TumorsCarcinoid Tumor+1 more
Fox Chase Cancer Center111 enrolled1 locationNCT05263050